Citations

Mayo Clinic

Showing 10 of 108523 citations.

Autonomic dysreflexia with relative tachycardia: Potential physiologic pathways for this head scratching clinical finding
Solinsky, Ryan , Singer, Wolfgang , Singer, Wolfgang , Solinsky, Ryan

PM&R | August 10, 2024 | Volume: 17 | Issue: 1 | Pages: 54-58

10.1002/pmrj.13247 | PMID 39126312 Get It

Minimally invasive posterior cervical foraminotomy versus the anterior transcorporeal approach for cervical radiculopathy: a systematic review and meta-analysis
Rajjoub, Rami , Nguyen, Ryan, El-Hajj, Victor Gabriel , Onyedimma, Chiduziem , Yolcu, Yagiz U. , Elmi‐Terander, Adrian , Bydon, Mohamad , Jarrah, Ryan , Elmi-Terander, Adrian , El-Hajj, Victor Gabriel , Nguyen, Ryan, Ghaith, Abdul Karim , Biase, Gaetano De , Akinduro, Oluwaseun O. , Abode-Iyamah, Kingsley

Journal of Neurosurgery: Spine | August 10, 2024 | Volume: 41 | Issue: 4 | Pages: 508-518

10.3171/2024.5.spine2497 | PMID 39126721 Get It

OBJECTIVE Surgical decompression is often indicated for symptomatic cases of cervical radiculopathy. In the cervical spine, minimally invasive posterior cervical foraminotomy (MIS-PCF) and the anterior transcorporeal approach (ATCA) are modern techniques available to surgeons. This systematic review and single-arm meta-analysis aimed to assess surgical and patient-reported outcomes of MIS-PCF and ATCA for cervical radiculopathy. METHODS A systematic review of the literature was conducted using 1) Ovid; 2) Epub Ahead of Print and In-Process, In-Data-Review & Other Non-Indexed Citations; and 3) Scopus databases, which reported outcomes following cervical decompression using MIS-PCF or the ATCA. Specifically, baseline characteristics, operative outcomes, and changes in visual analog scale (VAS) neck pain score were assessed. The quality of the studies was graded using the modified Newcastle-Ottawa Scale for observational studies. RESULTS Forty studies with 1661 patients were identified. The comparative analysis of both techniques revealed no significant differences in complication (7%, 95% CI 5%–10%, p = 0.75) or reoperation rates (5%, 95% CI 3%–7%, p = 0.41). Additionally, there were no significant differences in estimated blood loss (55.39, 95% CI 44.62–66.16 ml, p = 0.55) or operative time (85.15, 95% CI 65.38–104.92 minutes, p = 0.05). The ATCA showed significantly greater improvement (p < 0.01) in VAS neck pain scores following surgery (ATCA point reduction 6.7, 95% CI 6.0–7.5 points vs MIS-PCF 3.0, 95% CI 1.0–5.0 points). CONCLUSIONS The ATCA and MIS-PCF are effective modern techniques for the surgical treatment of radiculopathy. Both approaches showed comparable postoperative outcomes, including complication and reoperation rates. However, the ATCA was shown to provide significantly greater improvement in VAS neck pain scores.
The Impact of a Methicillin-Resistant Staphylococcus Aureus Nasal Polymerase Chain Reaction Protocol on Vancomycin Length of Therapy Among Patients With Skin and Soft Tissue Infections
Couzo, Anel, Griffin, Adia, Willis, Courtney , Mendez, Julio, Epps, Kevin , Willis, Courtney M , Epps, Kevin L

Journal of Pharmacy Practice | August 10, 2024 | Volume: 38 | Issue: 1 | Pages: 93-98

10.1177/08971900241273175 | PMID 39123306 Get It

Objective: We evaluated the impact of a methicillin-resistant Staphylococcus aureus (MRSA) nasal polymerase chain reaction (PCR) protocol on the vancomycin length of therapy (LOT) for skin and soft tissue infections (SSTIs). Design: Retrospective quasi-experimental pre- and post- MRSA nasal PCR protocol implementation study. Setting: Tertiary-care academic medical center in Jacksonville, Florida. Patients: Eligible patients received empiric vancomycin for SSTIs from January 1st to September 30th 2020 (pre-implementation group) and from January 1st to September 30th 2022 (post-implementation group). Intervention: The electronic health system software was modified to provide a best-practice advisory (BPA) prompt to the pharmacist upon order verification of vancomycin for patients with SSTIs. Methods: We reviewed patient records to determine the time from vancomycin prescription to de-escalation. The secondary outcomes were incidence of acute kidney injury (AKI), number of vancomycin levels collected, and hospital length of stay (LOS). Results: The study included 131 patients (pre-implementation, n = 86 and post-implementation, n = 45). There was no significant difference in vancomycin length of therapy (LOT) between implementation groups: mean LOT in days and standard deviation (SD) were 2.7 (1.9) and 2.6 (1.3), respectively, p-value 0.493. Of significance, in the post-implementation group, vancomycin LOT between patients with a negative and positive MRSA PCR were 2.3 (1.1) and 3.9 (1.6), p-value 0.006. There was no difference in secondary outcomes. Conclusion: The utilization of the MRSA nasal PCR to guide vancomycin de-escalation did not significantly change the vancomycin LOT, however in the post-implementation group there was a significant difference in vancomycin LOT between negative and positive MRSA PCRs.
Cabozantinib Plus Ipilimumab/Nivolumab in Patients With Previously Treated Advanced Differentiated Thyroid Cancer
Konda, Bhavana , Sherman, Eric J. , Morris, John C, Ryder, Mabel , Agulnik, Mark , Handley, Demond , Moses, Catherine, Jacob, Rajani, Streicher, Howard , Shah, Manisha H. , Streicher, Howard , Ryder, Mabel , Massarelli, Erminia , Nieva, Jorgé , Muzaffar, Jameel, Morris, John C, Ho, Alan L. , Wei, Lai , Moses, Catherine, Jacob, Rajani, Wright, John, Carson, William E.

The Journal of Clinical Endocrinology & Metabolism | August 9, 2024 | Volume: 110 | Issue: 3 | Pages: 830-837

10.1210/clinem/dgae512 | PMID 39133806 Get It

Abstract Background This investigator-initiated phase II trial aimed to evaluate the efficacy of cabozantinib in combination with nivolumab and ipilimumab (CaboNivoIpi) in previously treated patients with radioactive iodine-refractory differentiated thyroid cancer. Methods Eligible patients with radioactive iodine-refractory differentiated thyroid cancer who progressed on 1 prior line of vascular endothelial growth factor receptor-targeted therapy received a 2-week run-in of cabozantinib monotherapy followed by CaboNivoIpi for 4 cycles (cycle length = 6 weeks), followed by cabozantinib plus nivolumab (cycle length = 4 weeks) until disease progression. The primary endpoint was objective response rate (ORR) within the first 6 months of treatment. A Simon optimal 2-stage design allowed for an interim analysis after accrual of 10 evaluable patients. At least 5 responses were needed to proceed to stage 2. Results Among 11 patients enrolled, the median age was 69 years. Prior vascular endothelial growth factor receptor-targeted therapies included lenvatinib, pazopanib, and sorafenib plus everolimus. Median follow-up was 13.4 months. Among 10 evaluable patients, ORR within the first 6 months of treatment was 10% (1 partial response). Median progression-free survival was 9 months (95% CI, 3.0–not reached) and median overall survival was 19.2 months (95% CI, 4.6–not reached). Grade 3/4 treatment-related adverse events (AEs) were noted in 55% (6/11) and grade 5 AEs in 18% (2/11) of patients. The most common treatment-related AE was hypertension. The study did not reach its prespecified efficacy threshold. Conclusion CaboNivoIpi had low ORRs and a high rate of grade ≥3 treatment-related AEs. Clinical Trial Registration NCT03914300
Genomic Determinants of Outcome in Acute Lymphoblastic Leukemia
Chang, Ti‐Cheng , Chen, Wenan , Cheng, Zhongshan , Hedges, Dale J., Elsayed, Abdelrahman , Pounds, Stanley , Shago, Mary , Rabin, Karen R. , Raetz, Elizabeth A. , Cheng, Cheng , Angiolillo, Anne , Baviskar, Pradyuamna , Borowitz, Michael J., Carroll, Andrew J. , Carroll, William L. , Heerema, Nyla A. , Larsen, Eric , Mattano, Leonard A. , Maloney, Kelly W. , Ramirez, Nilsa C. , Salzer, Wanda L. , Wu, Gang , Loh, Mignon L. , Wu, Gang , Rabin, Karen R , Raetz, Elizabeth A , Devidas, Meenakshi , Baviskar, Pradyuamna , Burke, Michael J , Carroll, Andrew J , Harvey, Richard , Iacobucci, Ilaria , Wang, Jeremy R , Jeha, Sima , Mattano, Leonard A , Maloney, Kelly W , Pui, Ching-Hon , Ramirez, Nilsa C , Willman, Cheryl , Wood, Brent L , Hunger, Stephen P , Mullighan, Charles G , Loh, Mignon L , Pounds, Stanley B , Wu, Gang , Qu, Chunxu , Devidas, Meenakshi , Chen, I‐Ming , Harvey, Richard C. , Iacobucci, Ilaria , Wang, Jeremy , Willman, Cheryl L. , Winick, Naomi Joan , Wood, Brent L. , Hunger, Stephen P. , Mullighan, Charles G.

Journal of Clinical Oncology | August 9, 2024 | Volume: 42 | Issue: 29 | Pages: 3491-3503

10.1200/jco.23.02238 | PMID 39121442 Get It

PURPOSE Although cure rates for childhood acute lymphoblastic leukemia (ALL) exceed 90%, ALL remains a leading cause of cancer death in children. Half of relapses arise in children initially classified with standard-risk (SR) disease. MATERIALS AND METHODS To identify genomic determinants of relapse in children with SR ALL, we performed genome and transcriptome sequencing of diagnostic and remission samples of children with SR (n = 1,381) or high-risk B-ALL with favorable cytogenetic features (n = 115) enrolled on Children's Oncology Group trials. We used a case-control study design analyzing 439 patients who relapsed and 1,057 who remained in complete remission for at least 5 years. RESULTS Genomic subtype was associated with relapse, which occurred in approximately 50% of cases of PAX5 -altered ALL (odds ratio [OR], 3.31 [95% CI, 2.17 to 5.03]; P = 3.18 × 10 –8 ). Within high-hyperdiploid ALL, gain of chromosome 10 with disomy of chromosome 7 was associated with favorable outcome (OR, 0.27 [95% CI, 0.17 to 0.42]; P = 8.02 × 10 –10 ; St Jude Children's Research Hospital validation cohort: OR, 0.22 [95% CI, 0.05 to 0.80]; P = .009), and disomy of chromosomes 10 and 17 with gain of chromosome 6 was associated with relapse (OR, 7.16 [95% CI, 2.63 to 21.51]; P = 2.19 × 10 –5 ; validation cohort: OR, 21.32 [95% CI, 3.62 to 119.30]; P = .0004). Genomic alterations were associated with relapse in a subtype-dependent manner, including alterations of INO80 in ETV6::RUNX1 ALL, IKZF1 , and CREBBP in high-hyperdiploid ALL and FHIT in BCR::ABL1 -like ALL. Genomic alterations were also associated with the presence of minimal residual disease, including NRAS and CREBBP in high-hyperdiploid ALL. CONCLUSION Genetic subtype, patterns of aneuploidy, and secondary genomic alterations determine risk of relapse in childhood ALL. Comprehensive genomic analysis is required for optimal risk stratification.
A Protocol for the Inclusion of Minoritized Persons in Alzheimer Disease Research From the ADNI3 Diversity Taskforce
Okonkwo, Ozioma C. , Ashford, Miriam T. , Conti, Catherine , Strong, Joe, Raman, Rema , Nosheny, Rachel L. , Flenniken, Derek , Miller, Melanie J. , Diaz, Adam , Soto, Annabelle M., Ances, Beau M. , Beigi, Maryam , Doraiswamy, P. Murali , Duara, Ranjan , Farlow, Martin R. , Grossman, Hillel, Mintzer, Jacobo , Reist, Christopher , Rogalskı, Emily , Sabbagh, Marwan N. , Salloway, Stephen, Schneider, Lon S. , Petersen, Ronald C. , Aisen, Paul , Weiner, Michael W., Initiative, Alzheimer’s Disease Neuroimaging, Ances, Beau M , Mindt, Mónica Rivera , Donohue, Michael , Duara, Ranjan , Shah, Raj C. , Initiative, Alzheimer’s Disease Neuroimaging

JAMA Network Open | August 9, 2024 | Volume: 7 | Issue: 8 | Pages: e2427073

10.1001/jamanetworkopen.2024.27073 | PMID 39120898 Get It

ImportanceBlack or African American (hereinafter, Black) and Hispanic or Latino/a/x (hereinafter, Latinx) adults are disproportionally affected by Alzheimer disease, but most research studies do not enroll adequate numbers of both of these populations. The Alzheimer’s Disease Neuroimaging Initiative-3 (ADNI3) launched a diversity taskforce to pilot a multipronged effort to increase the study inclusion of Black and Latinx older adults.ObjectiveTo describe and evaluate the culturally informed and community-engaged inclusion efforts to increase the screening and enrollment of Black and Latinx older adults in ADNI3.Design, Setting, and ParticipantsThis cross-sectional study used baseline data from a longitudinal, multisite, observational study conducted from January 15, 2021, to July 12, 2022, with no follow-up. The study was conducted at 13 ADNI3 sites in the US. Participants included individuals aged 55 to 90 years without cognitive impairment and those with mild cognitive impairment or Alzheimer disease.ExposuresEfforts included (1) launch of an external advisory board, (2) changes to the study protocol, (3) updates to the digital prescreener, (4) selection and deployment of 13 community-engaged research study sites, (5) development and deployment of local and centralized outreach efforts, and (6) development of a community-science partnership board.Main Outcomes and MeasuresScreening and enrollment numbers from centralized and local outreach efforts, digital advertisement metrics, and digital prescreener completion.ResultsA total of 91 participants enrolled in the trial via centralized and local outreach efforts, of which 22 (24.2%) identified as Latinx and 55 (60.4%) identified as Black (median [IQR] age, 65.6 [IQR, 61.5-72.5] years; 62 women [68.1%]). This represented a 267.6% increase in the monthly rate of enrollment (before: 1.11 per month; during: 4.08 per month) of underrepresented populations. For the centralized effort, social media advertisements were run between June 1, 2021, and July 31, 2022, which resulted in 2079 completed digital prescreeners, of which 1289 met criteria for subsequent site-level screening. Local efforts were run between June 1, 2021, to July 31, 2022. A total of 151 participants underwent site-level screening (100 from local efforts, 41 from centralized efforts, 10 from other sources).Conclusions and RelevanceIn this cross-sectional study of pilot inclusion efforts, a culturally informed, community-engaged approach increased the inclusion of Black and Latinx participants in an Alzheimer disease cohort study.
Chromogranin A Deficiency Attenuates Tauopathy by Altering Epinephrine–Alpha-Adrenergic Receptor Signaling
Jati, Suborno , Muñoz-Mayorga, Daniel , Shahabi, Shandy , Tang, Kechun, Tao, Yuren, Dickson, Dennis W. , Chen, Xu , Mahata, Sushil , Dickson, Dennis W , Ghosh, Gourisankar , Chen, Xu , Litvan, Irene

No container title available | August 9, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4797912/v1 | PMID 39149499 Get It

Abstract Metabolic disorders such as insulin resistance and hypertension are potential risk factors for aging and neurodegenerative diseases. These conditions are reversed in Chromogranin A knockout (CgA-KO) mice. This study investigates the role of CgA in Alzheimer’s disease (AD) and corticobasal degeneration (CBD). CgA ablation in tauopathy mice (hTau) (CgA-KO/hTau) exhibited reduced tau aggregation, spreading, extended lifespan, and improved cognitive function. Transcriptomic and metabolite analysis of mouse cortices revealed altered alpha1-adrenergic receptors (Adra1) and high epinephrine (EPI) levels in hTau mice compared to WT mice, mirroring observations in AD and CBD patients. CgA-KO/hTau mice exhibited a reversal of EPI levels in the cortex and the expression of Adra1, nearly returning them to WT levels. Treatment of hippocampal slices with EPI or Adra1 agonist intensified, while an Adra1 antagonist inhibited tau hyperphosphorylation and aggregation. These findings highlight the interplay between the EPI-Adra signaling system and CgA in tauopathy.
Maternal Innate Immune Reprogramming After Complicated Pregnancy
Lodge‐Tulloch, Nakeisha A., Paré, Jean‐François , Couture, Camille , Bernier, Elsa, Cotechini, Tiziana , Girard, Sylvie , Graham, Charles H. , Sylvie, Girard

American Journal of Reproductive Immunology | August 9, 2024 | Volume: 92 | Issue: 2 | Pages: No page available

10.1111/aji.13908 | PMID 39119763 Get It

ABSTRACTProblemPreeclampsia (PE) and fetal growth restriction (FGR) are often associated with maternal inflammation and an increased risk of cardiovascular and metabolic disease in the affected mothers. The mechanism responsible for this increased risk of subsequent disease may involve reprogramming of innate immune cells, characterized by epigenetic modifications.Method of StudyCirculating monocytes from women with PE, FGR, or uncomplicated pregnancies (control) were isolated before labor. Cytokine release from monocytes following exposure to lipopolysaccharide (LPS) and the presence of lysine 4‐trimethylated histone 3 (H3K4me3) within TNF promoter sequences were evaluated. Single‐cell transcriptomic profiles of circulating monocytes from women with PE or uncomplicated pregnancies were assessed.ResultsMonocytes from women with PE or FGR exhibited increased IL‐10 secretion and decreased IL‐1β and GM‐CSF secretion in response to LPS. While TNFα secretion was not significantly different in cultures of control monocytes versus those from complicated pregnancies with or without LPS exposure, monocytes from complicated pregnancies had significantly decreased levels of H3K4me3 associated with TNF promoter sequences. Cluster quantification and pathway analysis of differentially expressed genes revealed an increased proportion of anti‐inflammatory myeloid cells and a lower proportion of inflammatory non‐classical monocytes among the circulating monocyte population in women with PE.ConclusionsMonocytes from women with PE and FGR exhibit an immune tolerance phenotype before initiation of labor. Further investigation is required to determine whether this tolerogenic phenotype persists after the affected pregnancy and contributes to increased risk of subsequent disease.
Severe Attrition and Poor Satisfaction in Patients Undergoing Telerehabilitation vs. Standard In-Person Rehabilitation after Arthroscopic Rotator Cuff Repairs and Anterior Cruciate Ligament Reconstructions
Vasavada, Kinjal , Shankar, Dhruv S. , Avila, Amanda, Mojica, Edward S. , Hurley, Eoghan T. , Lehane, Kevin , Buzin, Scott, Oeding, Jacob F. , Stein, Spencer , Gonzalez‐Lomas, Guillem , Alaia, Michael J. , Jazrawi, Laith M. , Campbell, Kirk A. , Oeding, Jacob F , Avila, Amanda , Strauss, Eric J.

Surgeries | August 9, 2024 | Volume: 5 | Issue: 3 | Pages: 627-639

10.3390/surgeries5030050 Get It

Background: The use of telerehabilitation after sports medicine procedures such as an arthroscopic rotator cuff repair (ARCR) and anterior cruciate ligament reconstruction (ACLR) has rapidly increased in recent years; however, the functional outcomes and patient satisfaction with telerehabilitation compared to in-person rehabilitation remain unclear. The purpose of this study was to compare the functional outcomes and patient satisfaction with telerehabilitation to in-person rehabilitation in a randomized controlled trial after two common sports procedures, ARCR and ACLR. Methods: Two randomized controlled trials were conducted involving patients scheduled to undergo ARCR or ACLR by one of six fellowship-trained sports medicine surgeons between October 2020 and November 2021. Each trial had an enrollment goal of 60 patients. Subjects were randomized 1:1 to receive telerehabilitation or in-person rehabilitation postoperatively. Functional outcome and satisfaction metrics were collected at baseline and at post-operative visits and compared between groups. Results: In total, 16 ACLR patients were enrolled, of whom 10 (62.5%) were assigned to in-person rehabilitation and 6 (37.5%) to telerehabilitation. Additionally, 32 ARCR patients were enrolled, of whom 20 (62.5%) were assigned in-person rehabilitation and 12 (37.5%) were assigned telerehabilitation. In total, of the 30 patients assigned to in-person rehabilitation, none reported a crossover to telerehabilitation. Of the 18 patients initially assigned to telerehabilitation, 12 (67%) completed the final follow-up survey, of which 11 (92%) reported a crossover; 9 patients completed in-person rehabilitation and 2 patients completed hybrid in-person and telerehabilitation. Conclusions: Patients preferred in-person rehabilitation compared to telerehabilitation after ACLR and ARCR, as evidenced by the nearly ubiquitous crossover from telerehabilitation to in-person rehabilitation in both studies. Our findings suggest that telerehabilitation protocols still need to be perfected, and that there may be a role for a hybrid in-person and tele-rehab model.
Aurora Kinase A Inhibition Potentiates Platinum and Radiation Cytotoxicity in Non-Small-Cell Lung Cancer Cells and Induces Expression of Alternative Immune Checkpoints
Liu, Huijie , Yang, Jihua , Tanwar, Ankit , Borczuk, Alain , Zhang, Dongwei , Chau, Vincent , Li, Shenduo , Ge, Xuan, Halmos, Balázs , Zang, Xingxing , Cheng, Haiying , Yang, Jihua , Tanwar, Ankit , Zhang, Dongwei , Chau, Vincent , Zang, Xingxing , Daylan, Ayse Ece Cali

Cancers | August 9, 2024 | Volume: 16 | Issue: 16 | Pages: 2805

10.3390/cancers16162805 | PMID 39199578 Get It

Despite major advances in non-small-cell lung cancer (NSCLC) treatment, the five-year survival rates for patients with non-oncogene-driven tumors remain low, necessitating combinatory approaches to improve outcomes. Our prior high-throughput RNAi screening identified Aurora kinase A (AURKA) as a potential key player in cisplatin resistance. In this study, we investigated AURKA’s role in platinum and radiation sensitivity in multiple NSCLC cell lines and xenograft mouse models, as well as its effect on immune checkpoints, including PD-L1, B7x, B7-H3, and HHLA2. Of 94 NSCLC patient tumor specimens, 91.5% tested positive for AURKA expression, with 34% showing moderate-to-high levels. AURKA expression was upregulated following cisplatin treatment in NSCLC cell lines PC9 and A549. Both AURKA inhibition by alisertib and inducible AURKA knockdown potentiated the cytotoxic effects of cisplatin and radiation, leading to tumor regression in doxycycline-inducible xenograft mice. Co-treated cells exhibited increased DNA double-strand breaks, apoptosis, and senescence. Additionally, AURKA inhibition alone by alisertib increased PD-L1 and B7-H3 expression. In conclusion, our study demonstrates that AURKA inhibition enhances the efficacy of platinum-based chemotherapy in NSCLC cells and modulates the expression of multiple immune checkpoints. Therefore, combinatory regimens with AURKA inhibitors should be strategically designed and further studied within the evolving landscape of chemo-immunotherapy.